100 related articles for article (PubMed ID: 18495790)
21. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
Le Tourneau C; Vidal L; Siu LL
Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
[TBL] [Abstract][Full Text] [Related]
22. The role of chromosomal alterations in human cancer development.
Gasparini P; Sozzi G; Pierotti MA
J Cell Biochem; 2007 Oct; 102(2):320-31. PubMed ID: 17722107
[TBL] [Abstract][Full Text] [Related]
23. Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions.
Teixeira MR
Am J Surg Pathol; 2008 Apr; 32(4):642-4; author reply 644. PubMed ID: 18317354
[No Abstract] [Full Text] [Related]
24. Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.
Annala M; Kivinummi K; Tuominen J; Karakurt S; Granberg K; Latonen L; Ylipää A; Sjöblom L; Ruusuvuori P; Saramäki O; Kaukoniemi KM; Yli-Harja O; Vessella RL; Tammela TL; Zhang W; Visakorpi T; Nykter M
Oncotarget; 2015 Mar; 6(8):6235-50. PubMed ID: 25749039
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers for prostate cancer.
Makarov DV; Loeb S; Getzenberg RH; Partin AW
Annu Rev Med; 2009; 60():139-51. PubMed ID: 18947298
[TBL] [Abstract][Full Text] [Related]
26. ETS transcription factors in endocrine systems.
Gutierrez-Hartmann A; Duval DL; Bradford AP
Trends Endocrinol Metab; 2007; 18(4):150-8. PubMed ID: 17387021
[TBL] [Abstract][Full Text] [Related]
27. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.
Lin DW
Urol Oncol; 2009; 27(3):315-21. PubMed ID: 19414121
[TBL] [Abstract][Full Text] [Related]
28. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Vis AN; Schröder FH
BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
Fradet Y
Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
[TBL] [Abstract][Full Text] [Related]
30. Congenital fibrosarcoma with a novel complex 3-way translocation t(12;15;19) and unusual histologic features.
Mariño-Enríquez A; Li P; Samuelson J; Rossi MR; Reyes-Múgica M
Hum Pathol; 2008 Dec; 39(12):1844-8. PubMed ID: 18657299
[TBL] [Abstract][Full Text] [Related]
31. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH
APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128
[TBL] [Abstract][Full Text] [Related]
32. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.
Shah N; Pang B; Yeoh KG; Thorn S; Chen CS; Lilly MB; Salto-Tellez M
Eur J Cancer; 2008 Oct; 44(15):2144-51. PubMed ID: 18715779
[TBL] [Abstract][Full Text] [Related]
33. Molecular Updates in Prostate Cancer.
Netto GJ
Surg Pathol Clin; 2015 Dec; 8(4):561-80. PubMed ID: 26612215
[TBL] [Abstract][Full Text] [Related]
34. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism.
Tamura K; Makino A; Hullin-Matsuda F; Kobayashi T; Furihata M; Chung S; Ashida S; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2009 Oct; 69(20):8133-40. PubMed ID: 19826053
[TBL] [Abstract][Full Text] [Related]
35. Genetic and epigenetic regulations of prostate cancer by genistein.
Molinié B; Georgel P
Drug News Perspect; 2009 Jun; 22(5):247-54. PubMed ID: 19609462
[TBL] [Abstract][Full Text] [Related]
36. [Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis].
Ohori M
Gan To Kagaku Ryoho; 2009 Jan; 36(1):6-10. PubMed ID: 19151558
[TBL] [Abstract][Full Text] [Related]
37. Absence of fusion of TMPRSS2 and ETS transcription factor genes in gastric and colorectal carcinomas.
Yoo NJ; Lee JW; Lee SH
APMIS; 2007 Mar; 115(3):252-3. PubMed ID: 17367471
[No Abstract] [Full Text] [Related]
38. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer. Multidisciplinary approach: a key to success.
Montagut C; Albanell J; Bellmunt J
Crit Rev Oncol Hematol; 2008 Oct; 68 Suppl 1():S32-6. PubMed ID: 18723370
[TBL] [Abstract][Full Text] [Related]
40. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells.
Tsui KH; Feng TH; Lin CM; Chang PL; Juang HH
J Androl; 2008; 29(6):661-8. PubMed ID: 18676361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
